2-(5-Bromo-2-Methylbenzyl)-5-(4-Fluorophenyl)thiophene CAS 1030825-20-7 Purity ≥98.0% (HPLC)

Kufotokozera Kwachidule:

2-(5-Bromo-2-Methylbenzyl)-5-(4-Fluorophenyl)thiophene

CAS: 1030825-20-7

Maonekedwe: Ufa Woyera Kapena Woyera

Kuyera: ≥98.0% (HPLC)

Intermediate of API (CAS: 842133-18-0) pochiza Type 2 Diabetes Mellitus

Inquiry: alvin@ruifuchem.com

Titumizireni imelo

Tsatanetsatane wa Zamalonda

Zogwirizana nazo

Zolemba Zamalonda

Kufotokozera:

Zapakati Zogwirizana ndi Opanga:
4-Fluorophenylboronic Acid CAS: 1765-93-1
2-(4-Fluorophenyl)thiophene CAS: 58861-48-6
2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone CAS: 32384-65-9
5-Iodo-2-Methylbenzoic Acid CAS 54811-38-0
2-(5-Bromo-2-Methylbenzyl)-5-(4-Fluorophenyl)thiophene CAS: 1030825-20-7
2-(4-Fluorophenyl) -5-[(5-iodo-2-methylphenyl)methyl]thiophene CAS: 898566-17-1
CAS: 842133-18-0
CAS: 928672-86-0

Chemical Properties:

Dzina la Chemical	2-(5-Bromo-2-Methylbenzyl)-5-(4-Fluorophenyl)thiophene
Nambala ya CAS	1030825-20-7
Nambala ya CAT	RF-PI234
Stock Status	Mu Stock, Kupanga Kukula Mpaka Mazana a Kilogram
Molecular Formula	Chithunzi cha C18H14BrFS
Kulemera kwa Maselo	361.27
Melting Point	103 ℃
Kuchulukana	1.388
Mtundu	Ruifu Chemical

Zofotokozera:

Kanthu	Zofotokozera
Maonekedwe	Ufa Woyera kapena Woyera
Kuyera / Kusanthula Njira	≥98.0% (HPLC)
Kutaya pa Kuyanika	≤1.00%
Zotsalira pakuyatsa	≤0.50%
Zitsulo Zolemera	≤20ppm
Test Standard	Enterprise Standard
Kugwiritsa ntchito	Pakati pa API (CAS: 842133-18-0)

Phukusi & Kusunga:

Phukusi: Botolo, Aluminiyamu zojambulazo thumba, 25kg/Cardboard Drum, kapena malinga ndi lamulo la kasitomala

Mkhalidwe Wosungira:Sungani m'mitsuko yosindikizidwa pamalo ozizira ndi owuma;Tetezani ku kuwala ndi chinyezi

Ubwino:

FAQ:

Ntchito:

Shanghai Ruifu Chemical Co., Ltd. ndi omwe amapanga 2-(5-Bromo-2-Methylbenzyl)-5-(4-Fluorophenyl)thiophene (CAS: 1030825-20-7) ndi apamwamba kwambiri.Iwondi yapakatikati mwa kaphatikizidwe ka API (CAS: 461432-26-8).API (CAS: 461432-26-8) ndi mankhwala atsopano a antidiabetic omwe amapangidwa pamodzi ndi Bristol-Myers Squibb ndi AstraZeneca, kuvomerezedwa ndi European Medicines Agency (EMA) pa November 12, 2012. Ndiwoyamba kuvomerezedwa SGLT2 inhibitor kwa chithandizo cha matenda a shuga a mtundu wachiwiri, kukhala njira yofunika kwambiri pochiza matenda a shuga, ndipo amagwiritsidwa ntchito popititsa patsogolo glycemic control monga chothandizira pazakudya komanso masewera olimbitsa thupi kwa akuluakulu omwe ali ndi matenda a shuga a mtundu wachiwiri.